The Use of Real-World Evidence (RWE) to Support Market Access of Medical Devices: Implications for the German Setting

Jacob C, Meise D, Mittendorf T, Braun S
Xcenda GmbH, Hannover, Germany

Presented at ISPOR 18th Annual European Congress | Milan, Italy | 7-11 November 2015

BACKGROUND

- Changes in German healthcare regulation strengthen the need for real-world evidence (RWE) analyses to support market access of medical devices.
- From 2016 on, the Act to Strengthen Health Care Provision within the Statutory Health Insurance System (Gesetz zur Stärkung der Versorgung in der gesetzlichen Krankenversicherung, §137h SGB V) requires high-risk or implantable, highly invasive medical devices (regulatory risk classes IIb and III) that are based on a new theoretical-scientific concept to undergo a benefit assessment.
- A benefit assessment will be mandatory if a hospital requests reimbursement under a special funding system that exists to cover additional resource use for new technologies. This funding scheme named the “New Diagnostic and Treatment Methods” (Neue Untersuchungs- und Behandlungsmethode [NUB]) system addresses, among other technologies, medical devices not yet covered by the G-DRG system.
- A 1-month period will be given to the manufacturer and hospitals seeking additional funding for using the respective medical device to provide information on its clinical benefits.
- Within the following 3 months, the Gemeinsame Bundesausschuss (GBA) will perform a benefit assessment that forms the basis for a decision on additional reimbursement.
- RWE offers various opportunities to address different information needs by diverse stakeholders on medical devices, and consequently, RWE analyses may act as an important instrument in supporting market access of medical devices.

OBJECTIVE

- The aim of this systematic literature review was to assess the current status of RWE studies in the field of medical devices for Germany.

METHODS

- A systematic literature review was conducted to depict the status quo of RWE studies in the field of medical devices for Germany.
- Relevant articles were identified via PubMed by keywords and MeSH terms linking various related terms for RWE and medical devices in the MEDLINE database of the United States National Library of Medicine (NLM).
- Titles and abstracts of potential studies were separately screened by 2 independent researchers. Studies were excluded if they did not describe the use of medical devices in a real-world setting in Germany in German/English language.
- Included studies were stratified by type of RWE data (registry data, administrative/claims data, medical charts, and other data sources), study design (prospective vs. retrospective), and research questions (brand-specific vs. non-brand-specific).

RESULTS

- Thirty-nine publications met the inclusion criteria and were included in the analyses.

CONCLUSIONS

- The majority of publications, about 74%, used a prospective study design (compared to retrospective studies at 26%).
- Two-thirds (66%) of the studies analyzed data on a product-specific level, whereas the remainder mainly distinguished between different categories of medical devices.

- Registry data were mostly used to address product-specific research questions (88%), while all claims data-based studies investigated research questions on a non-product-specific level.
- Stents are the most prominent research topic in RWE studies on medical devices. Most of these studies are based on 2 existing stent registries (DES.DE and Cypher).

- Common research questions were cost comparisons, survival analyses, and burden of disease.